Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG: Successful further development of sepsis and cancer drugs
Deutsche Biotech Innovativ AG / Key word(s): Final Results/AGM/EGM Deutsche Biotech Innovativ AG: Successful Further Development of Sepsis and Cancer Drugs Hennigsdorf, 12 June 2015 – Deutsche Biotech Innovativ AG (“DBI”) made great progress in its R&D activities in fiscal year 2014 and during the first months of 2015. The focus of its research was on innovative candidate drugs for the treatment of sepsis (severe systemic bacterial infection) and breast cancer prevention as well as cancer treatment. Within the last year and a half, the Hennigsdorf-based biotech company near Berlin was able to successfully expand its preclinical product pipeline by three drug candidates. Preclinical studies show promising results Adrecizumab, a humanized monoclonal antibody, developed by DBI is intended to be used for the causal and safe treatment of sepsis patients. The drug stabilizes the bioactivity of the peptide hormone adrenomedullin, thereby preventing organ failure during septic shock. After achieving very successful results during preclinical studies, DBI is currently preparing the phase I study. In addition, DBI is researching drugs for breast cancer prevention and cancer treatment. Aprepitant and AB2302 are two promising drug candidates. Aprepitant, an NK-1 receptor antagonist, is said to trigger controlled apoptosis (programmed cell death) in the presence of abnormal cells in women with an increased risk of breast cancer. The AB2302 antibody blocks adrenomedullin and restricts tumor growth by preventing the development of blood vessels. Annual financial statements for 2014: Higher R&D expenditures due to further development of the drug pipeline Deutsche Biotech Innovativ AG’s 2014 annual financial statements are available for download on the company’s website: This year’s annual general meeting will take place on 23 July 2015 in Berlin. About Deutsche Biotech Innovativ AG The members of the DBI Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have long-standing experience in the biotechnology field. Both were part of the founders’ and management team of B.R.A.H.M.S. AG, a very successful biotechnology company specializing in the determination of blood biomarker levels for treating serious illnesses, which was sold in 2009 for around EUR 330 million. Dr. Bernd Wegener is a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie). For more information, please contact: Deutsche Biotech Innovativ AG Kirchhoff Consult AG 2015-06-12 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
367965 2015-06-12 |